Assessment of tumor response to tyrosine kinase inhibitors

about

Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors.

P2860

Q28487987-E9A96660-14B3-4E7A-8865-A9F76AD4530C Q41972013-356A7BAE-5DC0-4E23-9D44-0013B888B2A3

P2860

Assessment of tumor response to tyrosine kinase inhibitors

Item

http://www.wikidata.org/entity/Q35558589

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Assessment of tumor response to tyrosine kinase inhibitors

@ast

Assessment of tumor response to tyrosine kinase inhibitors

@en

type

Item

label

Assessment of tumor response to tyrosine kinase inhibitors

@ast

Assessment of tumor response to tyrosine kinase inhibitors

@en

prefLabel

Assessment of tumor response to tyrosine kinase inhibitors

@ast

Assessment of tumor response to tyrosine kinase inhibitors

@en

P1476

Assessment of tumor response to tyrosine kinase inhibitors

@en

P2093

Amanda Lowery

http://www.w3.org/2001/XMLSchema#string

Zhaozhong Han

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular imaging in drug development

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer

Molecular imaging: 18F-FDG PET and a whole lot more.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues.

In vivo phage display and vascular heterogeneity: implications for targeted medicine.

Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells

Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.

Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.

P304

1996-2007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2741/3836

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21622159

http://www.w3.org/2001/XMLSchema#string

P932

4416055

http://www.w3.org/2001/XMLSchema#string

Assessment of tumor response to tyrosine kinase inhibitors

about

P2860

P2860

Assessment of tumor response to tyrosine kinase inhibitors

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932